Important drug interactions and reactions in dermatology

Dermatologic Clinics

Volumn 21, Issue 1, 2003, Pages 207-215

  Aria, Nancy ^a   Kauffman, C Lisa ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIFUNGAL AGENT; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; CYCLOSPORIN; DIGOXIN; ERYTHROMYCIN; ETRETIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; LEVOFLOXACIN; METHOTREXATE; MIDAZOLAM; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PHENYTOIN; PROBENECID; RIFAMPICIN; SILDENAFIL; SULFAMETHOXAZOLE; TERBINAFINE; TERFENADINE; TETRACYCLINE DERIVATIVE; THEOPHYLLINE; TRIAZOLAM; UNINDEXED DRUG; WARFARIN;

BIOAVAILABILITY; DERMATOLOGY; DIET SUPPLEMENTATION; DRUG ABSORPTION; DRUG METABOLISM; DRUG USE; ENZYME METABOLISM; HUMAN; HYDROXYLATION; LIVER METABOLISM; MULTIGENE FAMILY; PRIORITY JOURNAL; REVIEW;

ANTI-INFECTIVE AGENTS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DERMATOLOGIC AGENTS; DRUG INTERACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIDOCAINE; PHARMACEUTICAL PREPARATIONS; PRILOCAINE;

EID: 0037281470     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(02)00071-2     Document Type: Review

References (21)

1. Gupta AK, Katz HI, Shear NH. Drug interactions with itraconazole, fluconazole, and terbinafine and their management. J Am Acad Dermotol 1999;41:237-49.
2. Singer MI, Shapiro LE, Shear NH. Cytochrome P-4503A: interactions with dermatologic therapies. J Am Acad Dermatol 1997;37:765-71.
3. Hardman JG, Limbird LE, Molinoff PB, Ruddin RW. Goodman and Gilman's the pharmacological basis of therapeutics. 9th edition. New York: McGraw Hill; 1996.
4. Katzung B. Basic and clinical pharmacology. 7th edition. Stamford, CT: Appleton and Lange; 1998.
5. Anderson WK, Feingold DS. Adverse drug interactions clinically important for the dermatologist. Arch Dermatol 1995;131:468-73.
6. Barranco V. Clinically significant drug interactions in dermatology. J Am Acad Dermatol 1998;38:599-612.
7. Ehrenpreis ED, Ehrenpreis S. Cytochrome P-450 role in drug-induced hepatotoxicity. Clinics in Liver Disease 1998;2:457-70.
8. Anderson JR, Nawarskas JJ. Cardiovascular drug-drug interactions. Cardiol Clin 2001;19:215-34.
9. Epocrates.com Website. Available at: http://www.epocrates.com. Accessed December 12, 2002.
10. Ament PW, Bertolino JG, Liszewski JL. Clinically significant drug interactions: clinical pharmacology. Am Fam Physician 2000;61:1745-54.
11. Moossavi M, Baheri B, Scher R. Systemic antifungal therapy. Dermatol Clin 2001;19:35-52.
12. Le Cleach L, Bocquet H, Roujeau JC. Reactions and interactions of some commonly used systemic drugs in dermatology. Dermatol Clin 1998;16:421-9.
13. Sadick N. Systemic antibiotic agents. Dermatol Clin 2001;19:1-21.
14. Helms SE, Bredle DL, Zajic J, Jarjoura D, Brodell R, Krishnarao I. Oral contraceptive failure rates and oral antibiotics. J Am Acad Dermatol 1997;36:705-10.
15. Litt J. Drug eruption reference manual. New York: Parthenon Publishing Group; 2000.
16. Silvis NG. Antimetabolites and cytotoxic drugs. Dermatol Clin 2001;19:105-18.
17. Hansten PD, Horn JT. Drug interactions analysis and management. Facts and Comparisons. October 2000.
18. Lebwohl M, Ali S. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol 2001;45:649-61.
19. Cather JC, Abramounts W, Menter A. Cyclosporine and tacrolimus in dermatology. Dermatol Clin 2000;19:119-37.
20. www.powernetdesign.com/grapefruit. Website for Grapefruit Juice-Drug Interactions Homepage. Accessed December 2002.
21. Huang W, Vidimos A. Topical anesthetics in dermatology. J Am Acad Dermatol 2000;43:286-98.